KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biogen (BIIB) Non Operating Income (2016 - 2022)

Biogen has reported Non Operating Income over the past 14 years, most recently at -$263.3 million for Q1 2022.

  • For Q1 2022, Non Operating Income rose 48.06% year-over-year to -$263.3 million; the TTM value through Mar 2022 reached -$851.9 million, down 867.48%, while the annual FY2025 figure was -$305.6 million, 11.06% up from the prior year.
  • Non Operating Income for Q1 2022 was -$263.3 million at Biogen, down from -$182.1 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $683.5 million in Q4 2020 and troughed at -$506.9 million in Q1 2021.
  • A 5-year average of -$45.1 million and a median of -$41.0 million in 2018 define the central range for Non Operating Income.
  • Biggest five-year swings in Non Operating Income: crashed 472.17% in 2019 and later soared 1486.41% in 2020.
  • Year by year, Non Operating Income stood at -$28.6 million in 2018, then plummeted by 72.38% to -$49.3 million in 2019, then soared by 1486.41% to $683.5 million in 2020, then crashed by 126.64% to -$182.1 million in 2021, then tumbled by 44.59% to -$263.3 million in 2022.
  • Business Quant data shows Non Operating Income for BIIB at -$263.3 million in Q1 2022, -$182.1 million in Q4 2021, and -$502.9 million in Q3 2021.